Revance therapeutics, inc. (RVNC)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue

413

3,729

262

300

300

383

617

150

Operating expenses:
Research and development

102,861

92,500

80,361

50,381

47,529

33,390

27,831

19,557

Selling, general and administrative

62,011

53,863

37,398

29,075

25,088

19,043

11,011

12,356

Loss on impairment

0

0

2,927

9,100

0

0

-

-

Total operating expenses

164,872

146,363

120,686

88,515

72,617

52,433

38,842

31,913

Loss from operations

-164,459

-142,634

-120,424

-88,215

-72,317

-52,050

-38,225

-31,763

Interest income

5,532

4,023

1,410

1,170

231

44

2

76

Interest expense

0

44

457

1,082

1,190

10,672

15,164

444

Change in fair value of derivative liabilities associated with convertible notes

-

-

-

-

-

4,032

2,660

0

Changes in fair value of derivative liability

-199

-140

-591

-608

127

-320

47

47

Change in fair value of common stock warrant liability

-

-

-

-

-

2,151

621

0

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

-210

-743

0

Loss on settlement of preferred stock warrant

-

-

-

-

-

-1,356

0

0

Other expense, net

-303

-773

-525

-535

-327

-234

-404

-123

Loss before income taxes

-159,429

-139,568

-120,587

-89,270

-

-

-

-

Income tax provision

0

3,000

0

0

-

-

-

-

Net Income (Loss) Attributable to Parent

-159,400

-142,568

-120,587

-89,300

-73,476

-62,917

-52,448

-32,207

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

11

-8

45

-5

-40

0

0

12

Comprehensive loss

-159,418

-142,576

-120,542

-89,275

-73,516

-62,917

-52,448

-32,219

Net loss attributable to common stockholders:
Basic and diluted net loss

-159,429

-142,568

-120,587

-89,270

-73,476

-62,917

-

-

Basic

-

-

-

-

-

-

258

-32,207

Diluted

-

-

-

-

-

-

1,083

-32,207

Net loss per share attributable to common stockholders (Note 12):
Basic and diluted net loss (in dollar per share)

-3.67

-3.94

-4.01

-3.18

-3.02

-3.24

-

-

Basic (in usd per share)

-

-

-

-

-

-

1.17

-1.37

Diluted (in usd per share)

-

-

-

-

-

-

1.05

-1.37

Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)

43,460

36,171

30,101

28,114

24,340

19,391

-

-

Basic (in shares)

-

-

-

-

-

-

220

23,560

Diluted (in shares)

-

-

-

-

-

-

1,029

23,560